HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

AKCEA-APO(a)-LRx

hepatocyte-directed antisense oligonucleotide

Also Known As:

APO(a)-LRx

Networked: 5 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleotides: 15763
  - Polynucleotides: 218
    - Oligonucleotides: 5145
      - AKCEA-APO(a)-LRx: 5

Experts

1.	Nordestgaard, Børge G: 2 articles (01/2020 - 01/2019)
2.	Stroes, Erik S: 2 articles (01/2020 - 11/2016)
3.	Tsimikas, Sotirios: 2 articles (01/2020 - 11/2016)
4.	Viney, Nicholas J: 2 articles (01/2020 - 11/2016)
5.	Witztum, Joseph L: 2 articles (01/2020 - 11/2016)
6.	Xia, Shuting: 2 articles (01/2020 - 11/2016)
7.	Corsini, Alberto: 1 article (07/2020)
8.	Ezhov, Marat: 1 article (07/2020)
9.	Greco, Maria Francesca: 1 article (07/2020)
10.	Ruscica, Massimiliano: 1 article (07/2020)

Related Diseases

1.	Hyperlipoproteinemias 01/01/2019 - "Other therapeutic interventions, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, Lp(a) apheresis, and the novel antisense oligonucleotides APO(a)-Rx and APO(a)-LRx, which are being evaluated in ongoing clinical trials, have provided some promising results and can potentially be used in severe cases of hyperlipoproteinemia (a). "
2.	Cardiovascular Diseases (Cardiovascular Disease) 01/01/2019 - "However, a phase 3 study of AKCEA-APO(a)-LRx is being planned with cardiovascular disease as outcome, and results are awaited with great anticipation." 11/05/2016 - "IONIS-APO(a)-LRx might mitigate Lp(a)-mediated cardiovascular risk and is being developed for patients with elevated Lp(a) concentrations with existing cardiovascular disease or calcific aortic valve stenosis. " 01/01/2020 - "APO(a)-LRx reduced lipoprotein(a) levels in a dose-dependent manner in patients who had elevated lipoprotein(a) levels and established cardiovascular disease. "
3.	Injection Site Reaction 11/05/2016 - "IONIS-APO(a)-LRx was associated with no injection-site reactions. " 07/03/2020 - "In the era of RNA-based therapies, a new dawn is represented by the use of antisense oligonucleotides APO(a)Lrx, able to reduce Lp(a) from 35% to over 80%, with generally modest injection site reactions. "
4.	Human Influenza (Influenza) 01/01/2020 - "There were no significant differences between any APO(a)-LRx dose and placebo with respect to platelet counts, liver and renal measures, or influenza-like symptoms. "
5.	Aortic Valve Stenosis (Aortic Stenosis) 11/05/2016 - "IONIS-APO(a)-LRx might mitigate Lp(a)-mediated cardiovascular risk and is being developed for patients with elevated Lp(a) concentrations with existing cardiovascular disease or calcific aortic valve stenosis. "

Related Drugs and Biologics

1.	Antisense Oligonucleotides
2.	Apolipoproteins A
3.	PCSK9 Inhibitors
4.	Proprotein Convertase 9
5.	Lipoprotein(a)
6.	RNA (Ribonucleic Acid)

Related Therapies and Procedures

1.	Blood Component Removal (Apheresis)
2.	Therapeutics